Clinical trial
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of…
NCT00291330 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00291330 |
|---|---|
| Title | Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism |
| Official title | A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral… |
| Acronym | RE-COVER I |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug |
| Interventions | dabigatran etexilate 150 mg, warfarin (INR 2-3) |
| Enrollment | 2,564 |
| Start date | Feb 1, 2006 |
| Primary completion | May 1, 2009 |
| First posted | Feb 14, 2006 |
| Last update posted | Jun 6, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: